2 new glucagon antagonists may help treat type 2 diabetes

09/19/2011 | InternalMedicineNews.com (free registration)

A Phase I study on Eli Lilly and Co.'s LY2409021 drug and a Phase II trial on Merck & Co.'s MK-0893 drug each found significant reductions in blood glucose levels among type 2 diabetes patients, researchers reported at the European Society for the Study of Diabetes meeting. However, the glucagon receptor antagonists also increased liver enzymes and could trigger hypoglycemia and hyperglucagonemia.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD